Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Post Earnings of -$0.04 Per Share

Equities analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report ($0.04) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Enanta Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.11 and the lowest estimate coming in at ($0.27). Enanta Pharmaceuticals posted earnings per share of $0.97 during the same quarter last year, which would indicate a negative year-over-year growth rate of 104.1%. The business is expected to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of $1.53 per share for the current fiscal year, with EPS estimates ranging from $0.81 to $2.00. For the next financial year, analysts forecast that the business will post earnings of ($0.60) per share, with EPS estimates ranging from ($1.64) to $0.06. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.29. The firm had revenue of $39.60 million for the quarter, compared to analyst estimates of $40.92 million. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The business’s revenue was down 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share.

A number of brokerages have recently issued reports on ENTA. BidaskClub raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 24th. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 price target on the stock in a research note on Friday, May 10th. Finally, Berenberg Bank raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $114.40.

In related news, VP Yat Sun Or sold 10,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $103.53, for a total transaction of $1,035,300.00. Following the transaction, the vice president now owns 304,763 shares in the company, valued at $31,552,113.39. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director George Golumbeski sold 9,280 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $103.65, for a total value of $961,872.00. Following the transaction, the director now owns 9,280 shares in the company, valued at approximately $961,872. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,826 shares of company stock worth $2,150,473. 11.35% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Pearl River Capital LLC grew its stake in shares of Enanta Pharmaceuticals by 174.5% in the first quarter. Pearl River Capital LLC now owns 280 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 178 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Enanta Pharmaceuticals by 64.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 249 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at $49,000. Bank of Montreal Can grew its stake in shares of Enanta Pharmaceuticals by 33.0% in the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 216 shares in the last quarter. Finally, Prosight Management LP acquired a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at $68,000. Institutional investors own 86.86% of the company’s stock.

Shares of NASDAQ:ENTA traded up $0.68 during trading on Tuesday, reaching $90.96. The stock had a trading volume of 136,899 shares, compared to its average volume of 235,374. The firm has a market capitalization of $1.78 billion, a PE ratio of 26.14 and a beta of 1.30. Enanta Pharmaceuticals has a 1-year low of $64.08 and a 1-year high of $127.77.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.